What exactly changed in the PTCT analyst rating on Feb 20, 2026?

On **Feb 20, 2026** Cantor Fitzgerald **maintained an Overweight** rating on PTC Therapeutics. The action was a reiteration, not an upgrade or downgrade. The StreetInsider note listed no new price target and showed a **price change since** of **1.48% ($1.02)**

Does the Cantor Fitzgerald note include a new PTCT price target?

No. The Feb 20, 2026 note did not provide a new PTCT price target. Cantor Fitzgerald kept its Overweight rating and left its prior valuation view intact, according to the StreetInsider release.

How should investors interpret a maintained PTCT analyst rating?

A maintained PTCT analyst rating indicates continued analyst confidence but not fresh upside. Investors should combine the reiterated rating with company guidance, pipeline milestones, and Meyka’s **B+** grade before acting.

Where can I read the analyst note and recent company results?

Cantor Fitzgerald’s note is on StreetInsider, and company earnings and guidance are on Seeking Alpha. Both sources provide the primary analyst comment and the Q4 2025 earnings context used by analysts.

Analyst Ratings

Cantor Fitzgerald Keeps Overweight on PTC Therapeutics (PTCT) Feb 20 2026

ByHuzaifa Zahoor February 23, 2026February 23, 2026

On February 20, 2026 Cantor Fitzgerald maintained an Overweight rating on PTC Therapeutics, Inc., updating the PTCT analyst rating record. The firm left the stance unchanged rather than issuing an upgrade or downgrade. StreetInsider published the note, and Cantor Fitzgerald’s reiteration followed recent company results and guidance. Investors should view this action as continued analyst confidence, not a new bullish signal. The note listed price at time: N/A and showed a price change since of 1.48% ($1.02)